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Clinical Research
Acute Arterial Thromboembolism in Patients
with COVID-19 in the New York City Area
Yana Etkin, Allan M. Conway1, Jeffrey Silpe, Khalil Qato, Alfio Carroccio,
Pallavi Manvar-Singh, Gary Giangola, Jonathan S. Deitch, Luis Davila-Santini,
Jonathan A. Schor, Kuldeep Singh, Firas F. Mussa, and Gregg S. Landis, Hempstead

Background: Coronavirus disease 2019 (COVID-19) predisposes to arterial and venous
thromboembolic complications. We describe the clinical presentation, management, and outcomes of acute arterial ischemia and concomitant infection at the epicenter of cases in the
United States.
Methods: Patients with confirmed COVID-19 infection between March 1, 2020 and May 15,
2020 with an acute arterial thromboembolic event were reviewed. Data collected included demographics, anatomical location of the thromboembolism, treatments, and outcomes.
Results: Over the 11-week period, the Northwell Health System cared for 12,630 hospitalized
patients with COVID-19. A total of 49 patients with arterial thromboembolism and confirmed
COVID-19 were identified. The median age was 67 years (58e75) and 37 (76%) were men.
The most common preexisting conditions were hypertension (53%) and diabetes (35%). The
median D-dimer level was 2,673 ng/mL (723e7,139). The distribution of thromboembolic events
included upper 7 (14%) and lower 35 (71%) extremity ischemia, bowel ischemia 2 (4%), and cerebral ischemia 5 (10%). Six patients (12%) had thrombus in multiple locations. Concomitant
deep vein thrombosis was found in 8 patients (16%). Twenty-two (45%) patients presented
with signs of acute arterial ischemia and were subsequently diagnosed with COVID-19. The
remaining 27 (55%) developed ischemia during hospitalization. Revascularization was performed in 13 (27%) patients, primary amputation in 5 (10%), administration of systemic tissueplasminogen activator in 3 (6%), and 28 (57%) were treated with systemic anticoagulation only.
The rate of limb loss was 18%. Twenty-one patients (46%) died in the hospital. Twenty-five
(51%) were successfully discharged, and 3 patients are still in the hospital.
Conclusions: While the mechanism of thromboembolic events in patients with COVID-19 remains unclear, the occurrence of such complication is associated with acute arterial ischemia
which results in a high limb loss and mortality.

Type of Research: Retrospective analysis of the largest reported single
health system experience with COVID-19 presenting with acute arterial
thrombosis from the United States’ epicenter of the infection.
Key Findings: COVID-19 is a risk factor for acute arterial thrombosis and carries poor prognosis in terms of mortality and morbidity.
Take Home Message: Patients with confirmed COVID-19 are at
increased risk for thromboembolic complications and early diagnosis,
and treatment is critical. Despite all attempts for life and limb salvage,
the overall outcome is largely driven by the patient’s physiologic state at
presentation.
Table of Contents Summary: We report the clinical presentation,
management, and outcomes of acute arterial ischemia and concomitant
infection at the epicenter of cases in the United States.
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INTRODUCTION
In December 2019, a series of pneumonia cases of
unknown origin were identified in Wuhan, China.1
The pathogen has since been identified as a novel
enveloped RNA beta-coronavirus that has been
named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).2 The first confirmed case of
coronavirus disease 2019 (COVID-19) in the United
States was reported in Washington State in January
2020.3 Although the typical presentation involves
viral pneumonia causing severe respiratory deterioration, a hypercoagulable state has been observed in
many patients with SARS-CoV-2 and is a predictor
of a worse prognosis.1,4,5
COVID-19 may predispose to both arterial and
venous thromboembolic complications.6 The cumulative incidence of thrombotic complications in critically ill patients with COVID-19 was 31% despite
systemic thromboprophylaxis, including 27%
venous thromboembolisms and 4% arterial thrombotic events.6 Arterial thromboembolic complications may have devastating consequences,
including limb loss, premature intubation, multiorgan dysfunction, stroke, and death.
The purpose of this study was to review the incidence, clinical presentation, management, and outcomes with 46 consecutive cases with acute arterial
thrombosis in patients with confirmed COVID-19.

METHODS
A study was conducted at 7 hospitals within Northwell Health, the largest academic health system in
New York State, serving approximately 11 million
persons. All patients with confirmed COVID-19
infection and acute arterial thrombosis from March
1, 2020 to May 15, 2020 were entered into a
Research Electronic Data Capture tools hosted at
Northwell Health.7 These patients were identified
based on retrospective review of prospectively
maintained database of all inhospital consultations.
Research Electronic Data Capture is a secure, webbased application designed to support data capture
for research studies, providing: 1) an intuitive interface for validated data entry; 2) audit trails for
tracking data manipulation and export procedures;
3) automated export procedures for seamless data
downloads to common statistical packages; and 4)
procedures for importing data from external sources. The Northwell Health Institutional Review
Board approved this case series as minimal-risk
research using data collected for routine clinical
practice and waived the requirement for informed
consent.
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Data collected included patient demographic information, comorbidities, anatomical location, and
clinical presentation of thromboembolism, treatment, and clinical outcomes. Race and sex data
were collected by self-report in prespecified fixed
categories. The Northwell COVID survival calculator
was used to assess for expected mortality. This tool
was constructed using multivariate regression with
L1 regularization (LASSO) to predict survival during
hospitalization, based on outcomes of 5,233 patients
with COVID-19 hospitalized at Northwell Health.
Patient age, serum blood urea nitrogen, Emergency
Severity Index, red cell distribution width, absolute
neutrophil count, serum bicarbonate, and glucose
were identified as the optimal predictors of survival
by multivariate LASSO regression.8
All statistics were performed as a descriptive analysis. Continuous variables were expressed as medians and interquartile ranges. Categorical variables
were summarized as counts and percentages.

RESULTS
During the study period, the Northwell Health System cared for 12,630 hospitalized patients with
COVID-19. The initial characteristics of 5,700 patients from Northwell are presented elsewhere.9
This case series presents indepth results on 49 patients with acute arterial thromboembolisms and
COVID-19 were not presented in that article. The
median age was 67 years, and 76% were men
(Table I). Based on Northwell COVID-19 survival
calculator, median-predicted mortality at the time
of vascular evaluation was 37% (IQR ¼ 11e94).
Thirteen patients (27%) were severely ill and were
intubated before onset of ischemia. The median Ddimer level was 2,673 (IQR ¼ 723e7,139), and
83% of patients had D-dimer greater than
1,000 ng/mL. Twenty-two (45%) patients presented
with signs of acute arterial ischemia and were subsequently diagnosed with COVID-19. Twenty-seven
patients (55%) developed ischemia during hospitalization after an average of 6 ± 4.5 days.
The distribution of ischemia included upper
(14%) and lower (71%) extremity, mesenteric
(4%), and cerebral (10%). Six patients (12%) had
concomitant arterial thrombus in multiple anatomic
locations (Table II). Sixteen percent had concomitant deep vein thrombosis. Computed tomography
angiogram was diagnostic in 25 patients (51%)
and duplex ultrasound in 19 (39%). The remaining
5 patients were too unstable for transport to imaging, and the diagnosis was based on clinical signs
of acute ischemia.
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Table I. Demographics and comorbiditiesa
Characteristics

N ¼ 49 (%)

Median age (IQR), year
Gender (%male), n (%)
Race, n (%)
Caucasian
African American
Hispanic
Asian
Median BMI (IQR), kg/m2
Comorbidities, n (%)
Hypertension
Diabetes mellitus
Chronic obstructive
pulmonary disease
Heart disease
Chronic kidney disease
Hypercholesterolemia
Peripheral vascular disease
Atrial fibrillation
Smoking
Active smokers
Ex-smokers
Malignancy
Multiple comorbidities
No past medical history
Home medications
Antiplatelets
Anticoagulants

67 (58e75)
37 (76)
17
9
17
6
28

(35)
(18)
(35)
(12)
(25e32)

26 (53)
17 (35)
3 (6)
8
2
12
2
7
9
2
7
7
22
13

(16)
(4)
(24)
(4)
(14)
(18)
(4)
(14)
(14)
(45)
(27)

14 (29)
7 (14)

Race and ethnic group were reported by the patient or were
determined by family or physician if patient was noncommunicative.
a
Percentages may not total 100 because of rounding. IQR denotes interquartile range.

Of the 35 patients with lower extremity
ischemia, 9 received open thrombectomy, 2 endovascular thrombectomy, and 5 primary amputations. Of the 2 patients with mesenteric
ischemia, 1 underwent open thrombectomy and
1 endovascular thrombolysis. A total of 28 patients
(57%) were treated with systemic anticoagulation,
3 (7%) received a single weight-based dose of recombinant tissue plasminogen activator, of those,
19 (61%) were deemed too unstable for surgical
interventions.
The rate of limb loss was 18%, and overall,
inhospital mortality was 46%. Mortality in patients with lower limb ischemia was 50%, and
in patients with mesenteric ischemia, it was
100%. Twenty-five patients (51%) were successfully discharged from hospital, and 3 (6%)
remain hospitalized at the time this manuscript
was prepared.

Table II. Symptoms and anatomic location of the
thromboembolisma
Symptoms and location of arterial occlusion

N (%)

Lower extremity ischemia
Aortoiliac
Femoral above knee
Popliteal below knee
Upper extremity ischemia
Upper arm (subclavian,
axillary and brachial)
Forearm (ulnar and radial)
SMA thrombosis with bowel ischemia
Renal artery thrombosis
Splenic artery thrombosis
CVA with carotid artery thrombosis
Asymptomatic with thoracic
aortic thrombus
Thrombosis in multiple locationsb

35
8/35
12/35
15/35
7
4/7

(71)
(23)
(34)
(43)
(14)
(57)

3/7
2
5
3
5
1

(43)
(4)
(10)
(6)
(10)
(2)

6 (12)

a

Percentages may not total 100 because of rounding.
Concomitant thrombus in the SMA, renal arteries, and lower
and upper extremity arteries. SMA denotes superior mesenteric
artery and CVA cerebrovascular accident.
b

DISCUSSION
SARS-CoV are an emerging and reemerging source
of global pandemic (e.g., SARS, Middle East respiratory syndrome (MERS), and COVID-19) which have
caused significant morbidity and mortality, most
notably in the last several months. Although the
typical presentation involves viral pneumonia with
severe respiratory deterioration,4 abnormal coagulation occurs in many patients with COVID-19 population and is a predictor of worse prognosis1,5,10,11
Furthermore, COVID-19 may predispose to both
arterial and venous thromboembolic complications.6,12e14 To our knowledge, this report represents the largest case series of acute arterial
ischemic complications in patients with COVID-19
to date. Of 12,630 patients who were hospitalized
in our system with COVID-19, 49 patients were
diagnosed with acute arterial ischemia and 16% of
them had concipient venous thromboembolisms.
Acute arterial ischemic events were noted as the
presenting symptom in 45% of our patients suggesting that a diagnosis of COVID-19 should be considered in any patient presenting with arterial
ischemia. It remains unclear if any of the thromboembolic events in our series were a result of paradoxical embolism in the setting of a patent
foramen ovale. The routine use of echocardiography
with agitated saline was avoided due to the concern
for aerosolization of the virus.
Our patients were predominantly men over the
age of 65 years with multiple comorbidities which
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is compatible with other reports from China and the
United States,9,15 which demonstrated increase
prevalence of severe COVID-19 infection and worse
outcomes in this subset of patients. The overall mortality in our cohort was significantly higher (46%)
than 21e26% reported in other studies of hospitalized patients with COVID-19.9,15 We also observed
worse outcomes in patients with acute lower limb
ischemia with mortality of 50% as than 5e9% reported in a non-COVID-19 population.16,17 Mortality from acute mesenteric ischemia is between 22%
and 50%,18,19 far lower than the 100% rate
observed in our series. However, it is difficult to
draw any meaningful conclusions based on our
data due to very small sample size. This difference
in mortality further supports the fact that hypercoagulable state in patients with SARS-COV-2 is a predictor of worse prognosis.
Inflammation secondary to viral infection has
been a key component leading to a procoagulant
state; this phenomenon is secondary to a myriad of
factors including tissue factoredependent activation
of the coagulation cascade secondary to endothelial
cell injury and dysfunction, elevated levels of von
Willebrand factor, and toll-like receptor activation
of proinflammatory cytokines.20 Historically,
SARS-CoV-1 and MERS-CoV also exhibited similar
prothrombotic complications, as well as thrombocytopenia.21 Furthermore, disseminated intravascular
coagulation was a prevalent complication in many
of the fatal MERS-CoV cases.22 Many patients with
COVID-19 infection present with thrombocytopenia and elevated D-dimer levels, which are
augmented in the most severe forms of the disease.23 Nonsurvivors of COVID-19 have been
shown to have higher D-dimer and fibrin degradation product levels, with longer prothrombin times,
associated with coagulation dysfunction. In our
cohort, all patients had elevated D-dimer levels
and 83% of patients had D-dimer greater than
1,000 ng/mL. We observed 77% mortality in patients with D-dimer levels over 5,000 ng/mL.
Elevated D-dimer levels reiterate the acquired hypercoagulability in these patients as well as inflammatory state. With further research, these levels
may help to predict which patients with COVID-19
will develop thromboembolic complications and
subsequently worse outcomes.
Previous coronavirus and influenza epidemics
have suggested that viral infections can trigger acute
coronary syndromes, arrhythmias, and exacerbation of heart failure.24,25 Huang and et al. reported
12% incidence of acute cardiac injury in patients
with COVID-19. In this series, 16% of patients had
preexisting cardiac disease and 14% had history of
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arrhythmias. Given the baseline cardiovascular disease, the development of arrhythmias, and the hypercoagulable states in patients with SARS-CoV-2
infection, the potential to develop thromboembolic
disease is understandably high.

LIMITATIONS
This study has several limitations. It is a retrospective descriptive review with no direct comparison
with patients without COVID-19 infection (control
group). We were not able to investigate a direct
cause-effect mechanism and that was not the intention of this review. With the limited number of
cases, it is also difficult to assess risk factors for disease distribution and outcomes. In addition, some
patients remained in the hospital, and the outcomes
were unknown at the time of data cutoff. Finally,
this series is likely an under-representation of the
true incidence of acute arterial thromboembolic
events in patients with COVID-19, as both asymptomatic cases, and acute arterial ischemic events in
moribund patients were likely never diagnosed.

CONCLUSION
In this series of patients with COVID-19 and acute
arterial ischemia, presentation varied from asymptomatic to nonsalvageable. Prognosis was largely
driven by the overall physiologic condition of the
patient at presentation and also by duration of
symptoms and was generally poor. The limb loss
rate was high at 18%, and overall mortality was
46%. Eighty-three percent of patients had elevated
D-dimer levels greater than 1,000 ng/mL. In patients with COVID-19, hypercoagulability is likely
related to an inflammatory cascade with cytokine
storm secondary to sepsis, possible disseminated
intravascular coagulation, and excessive activation
of the coagulation cascade. Arterial thromboembolic
complications carry devastating consequences of
limb loss, multiorgan dysfunction, and death. A
diagnosis of COVID-19 should be considered in
any patient presenting with arterial ischemia.

The Northwell COVID-19 Research consortium.
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